Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Exclusion Criteria

• •Currently taking any oral urate-lowering medication within 2 weeks prior to Screening
• •Prior uricase therapy or exposure to recombinant uricase, such as Rasburicase or Pegloticase
• •Gout flare requiring treatment within 14 days prior to or during Screening
• •Clinically significant finding during Screening, any ongoing clinically significant illness requiring a clinically significant intervention or change in management within 4 weeks prior to or during Screening
• •History of GI surgery, including gastric sleeve, Roux-en-Y or gastric banding (unless gastric band removed for a minimum of 12 months prior to Screening
• •Received treatment with or exposure to an Investigational drug or device within 30 days - prior to or during Screening
• •Prior dosing in ALLN-346 clinical study
• •Per Investigator judgment, is not an ideal clinical study candidate